September 09, 2020
HOUSTON, Sept. 9, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it successfully completed a...
Source URL: https://www.prnewswire.com:443/news-releases/moleculin-announces-successful-completion-of-pre-ind-meeting-with-the-fda-301126161.html
|
